Abstract
Background School closures are a well-established non-pharmaceutical intervention in the event of infectious disease outbreaks, and have been implemented in many countries across the world, including the UK, to slow down the spread of SARS-CoV-2. As governments begin to relax restrictions on public life there is a need to understand the potential impact that reopening schools may have on transmission.
Methods We used data provided by the UK Department for Education to construct a network of English schools, connected through pairs of pupils resident at the same address. We used the network to evaluate the potential for transmission between schools, and for long range propagation across the network, under different reopening scenarios.
Results Amongst the options evaluated we found that reopening only Reception, Year 1 and Year 6 (4-6 and 10-11 year olds) resulted in the lowest risk of transmission between schools, with outbreaks within a single school unlikely to result in outbreaks in adjacent schools in the network. The additional reopening of Years 10 and 12 (14-15 and 16-17 year olds) resulted in an increase in the risk of transmission between schools comparable to reopening all primary school years (4-11 year olds). However, the majority of schools presented low risk of initiating widespread transmission through the school system. Reopening all secondary school years (11-18 year olds) resulted in large potential outbreak clusters putting up to 50% of households connected to schools at risk of infection if sustained transmission within schools was possible.
Conclusions Reopening secondary school years is likely to have a greater impact on community transmission than reopening primary schools in England. Keeping transmission within schools limited is essential for reducing the risk of large outbreaks amongst school-aged children and their household members.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The following funding sources are acknowledged as providing funding for the named authors. This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: WJE). This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (PR-OD-1017-20002: WJE). Health Protection Research Unit for Immunisation NIHR200929: AJvH, JDM, KEA. UK MRC (MC_PC_19065: WJE). Wellcome Trust (210758/Z/18/Z: JDM, JH, KS, NIB, SA, SFunk, SRM). No funding (JW). The following funding sources are acknowledged as providing funding for the working group authors. Alan Turing Institute (AE). BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: KP, MJ, YL; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1180644: SRP; OPP1183986: ESN; OPP1191821: KO'R, MA). BMGF (OPP1157270: KA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP, KvZ). DTRA (HDTRA1-18-1-0051: JWR). Elrha R2HC/UK DFID/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). ERC Starting Grant (#757699: JCE, MQ, RMGJH). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, RCB, YL). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: AG, CIJ, TJ). HDR UK (MR/S003975/1: RME). Nakajima Foundation (AE). NIHR (16/136/46: BJQ; 16/137/109: BJQ, CD, FYS, MJ, YL; Health Protection Research Unit for Immunisation NIHR200929: NGD; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ; NIHR200929: MJ; PR-OD-1017-20002: AR). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1: GRGL, QJL; MC_PC_19065: AG, NGD, RME, SC, TJ, YL; MR/P014658/1: GMK). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB; 208812/Z/17/Z: SC, SFlasche). No funding (AKD, AMF, CJVA, DCT, SH, YWDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
LSHTM Ethics Committee approval reference: 22476
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The following authors were part of the Centre for Mathematical Modelling of Infectious Disease COVID-19 working group. Each contributed in processing, cleaning and interpretation of data, interpreted findings, contributed to the manuscript, and approved the work for publication: Rosalind M Eggo, David Simons, Kathleen O’Reilly, Timothy W Russell, Rachel Lowe, Quentin J Leclerc, Jon C Emery, Petra Klepac, Emily S Nightingale, Matthew Quaife, Kevin van Zandvoort, Gwenan M Knight, Thibaut Jombart, C Julian Villabona-Arenas, Eleanor M Rees, Charlie Diamond, Megan Auzenbergs, Graham Medley, Anna M Foss, Georgia R Gore-Langton, Arminder K Deol, Mark Jit, Hamish P Gibbs, Simon R Procter, Alicia Rosello, Christopher I Jarvis, Yang Liu, Rein M G J Houben, Stéphane Hué, Samuel Clifford, Billy J Quilty, Amy Gimma, Damien C Tully, Fiona Yueqian Sun, Kiesha Prem.
Data Availability
The data used for this analysis is sensitive and therefore not shareable.
